On the other hand, it should be noted that improperly-performed paraffin embedding damages DNA and can favor methods that are more robust to variation in the amount and quality of the starting material (this would arguably disfavor TheraScreen because it requires eight PCR reactions whereas the other methods HDAC cancer require only one equivalent reaction). It has been suggested that the issue of limited material for testing can be largely circumvented by using whole genome amplification techniques [39, 40], although the potentially biasing impact of the genome amplification techniques on low frequency somatic mutation genotyping is still not fully addressed.

However, we suppose that our tests of kit performance on frozen tissue samples provide useful insights into their general utility and will be valuable for orchestrating genotyping efforts across molecular pathology laboratories. Conclusions The performance of five methods (Direct sequencing, Pyrosequencing, High resolution melting analysis, the TheraScreen DxS kit, C188-9 mouse and the K-ras StripAssay) for Selleck PARP inhibitor detecting mutations in the KRAS gene was compared using DNA extracted from 131 frozen NSCLC samples. The TheraScreen DxS kit was found to be the most effective, followed by the StripAssay kit. However, because of the heterogeneity of typical cancer tissue samples and the differences in the two methods’ mechanisms

of action, there are still unsatisfactory numbers of discrepancies between these two ‘best’ methods, which failed to agree on 8 of the 131 specimens examined in this work. Nevertheless, our findings

should facilitate the rational selection of methods for detecting mutations at the KRAS locus using heterogeneous clinical samples obtained from biopsies of cancer patients. Acknowledgements This research was supported by grants from the Ministry of Industry and Trade not (MPO TIP FR-TI1/525), and the Ministry of Health of the Czech Republic (NT 13569 and NS 9959) and Internal Grant Agency of Palacky University (IGA UP VG911100371/32). Infrastructural part of this project (Institute of Molecular and Translational Medicine) was supported by the Operational Program “Research and Development for Innovations” (project CZ.1.05/2.1.00/01.0030). References 1. Jancik S, Drabek J, Radzioch D, Hajduch M: Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010., 2010: 150960. 1–13, Epub 2010 Jun 7 2. Lorigan P, Califano R, Faivre-Finn C, Howell A, Thatcher N: Lung cancer after treatment for breast cancer. Lancet Oncol 2010, 11:1184–1192.PubMedCrossRef 3. Matesich SM, Shapiro CL: Second cancers after breast cancer treatment. Semin Oncol 2003, 30:740–748.PubMedCrossRef 4. Vasudevan KM, Garraway LA: AKT signaling in physiology and disease. Curr Top Microbiol Immunol 2010, 347:105–133.PubMedCrossRef 5.